03:00 Mon 07 Oct 2019
MaxCyte, Inc. - Editas Clinical and Commercial License Agreement
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
Under the terms of the agreement, Editas Medicine obtains non-exclusive clinical and commercial use rights to
"We look forward to working with
"We are excited to work with Editas Medicine as it is at the forefront of developing engineered cell medicines that have the potential to change the course of disease for many patients. This agreement is also a significant business milestone for
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
About
Editas Medicine Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Editas Medicine's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicine's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in Editas Medicine's most recent Quarterly Report on Form 10-Q, which is on file with the
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
###
Contacts:
|
+1 301 944 1660 |
Editas Medicine Media
|
+1 (617) 401-0113 |
Nominated Adviser and Joint Corporate Broker Corporate Broking
|
+44 (0)20 7886 2500 |
Joint Corporate Broker |
+44 (0)20 7260 1000 |
Financial PR Adviser
|
+44 (0)203 709 5700 |
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE